Evidence map›Paper›PMID 33808036›Full record

ReviewBiomolecules2021

Intracellular Toxic AGEs (TAGE) Triggers Numerous Types of Cell Damage.

Masayoshi Takeuchi, Akiko Sakasai-Sakai, Takanobu Takata, Jun-Ichi Takino, Yoshiki Koriyama, Chigusa Kikuchi, Ayako Furukawa, Kentaro Nagamine, Takamitsu Hori, Tamihide Matsunaga

Open access · goldAbstract readReview
In one paragraph

Review in Biomolecules, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
5.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 45 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Narra J · 2025
    Article
  6. Review
  7. Review
  8. Meloxicam mitigated methylglyoxal-induced glycative stress in rats.Iranian journal of basic medical sciences · 2025
    Article
  9. Review
  10. Review
  11. Toxic AGEs (TAGE) Cause Lifestyle-Related Diseases.Antioxidants (Basel, Switzerland) · 2024
    Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Masayoshi TakeuchiDepartment of Advanced Medicine, Medical Research Institute, Kanazawa Medical University, 1-1 Daigaku, Uchinada-machi, Ishikawa 920-0293, Japan.ORCID 0000-0002-1057-3764
Akiko Sakasai-SakaiDepartment of Advanced Medicine, Medical Research Institute, Kanazawa Medical University, 1-1 Daigaku, Uchinada-machi, Ishikawa 920-0293, Japan.ORCID 0000-0002-1258-1725
Takanobu TakataDepartment of Advanced Medicine, Medical Research Institute, Kanazawa Medical University, 1-1 Daigaku, Uchinada-machi, Ishikawa 920-0293, Japan.ORCID 0000-0003-0514-8584
Jun-Ichi TakinoDepartment of Biochemistry, Faculty of Pharmaceutical Sciences, Hiroshima International University, 5-1-1 Hirokoshingai, Kure, Hiroshima 737-0112, Japan.
Yoshiki KoriyamaGraduate School and Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, 3500-3 Minamitamagaki, Suzuka, Mie 513-8670, Japan.ORCID 0000-0001-8777-329X
Chigusa KikuchiDepartment of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya 467-8603, Japan.ORCID 0000-0001-5809-8889
Ayako FurukawaGraduate School and Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, 3500-3 Minamitamagaki, Suzuka, Mie 513-8670, Japan.
Kentaro NagamineDepartment of Clinical Nutrition, Faculty of Health Sciences, Hiroshima International University, 5-1-1 Hirokoshingai, Kure, Hiroshima 737-0112, Japan.
Takamitsu HoriDepartment of Biochemistry, Faculty of Pharmaceutical Sciences, Hiroshima International University, 5-1-1 Hirokoshingai, Kure, Hiroshima 737-0112, Japan.
Tamihide MatsunagaDepartment of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya 467-8603, Japan.
Hiroshima International University · JPKanazawa Medical University · JPNagoya City University · JPSuzuka University of Medical Science · JP

Funding

JSPS KAKENHI 16H01811 (M.T.)JSPS KAKENHI 18K11003 (A.S.-S.)JSPS KAKENHI 18K11036 (T.H.)JSPS KAKENHI 18K11139 (T.T.)JSPS KAKENHI 19H03391 (T.M.)JSPS KAKENHI 19K11781 (Y.K.)KAKEN Grant for Assistance from Kanazawa Medical University K2019-24 (M.T.)KAKEN Grant for Assistance from Kanazawa Medical University K2020-26 (M.T.)
6 · The paper itself

Abstract

The habitual intake of large amounts of sugar, which has been implicated in the onset/progression of lifestyle-related diseases (LSRD), induces the excessive production of glyceraldehyde (GA), an intermediate of sugar metabolism, in neuronal cells, hepatocytes, and cardiomyocytes. Reactions between GA and intracellular proteins produce toxic advanced glycation end-products (toxic AGEs, TAGE), the accumulation of which contributes to various diseases, such as Alzheimer's disease, non-alcoholic steatohepatitis, and cardiovascular disease. The cellular leakage of TAGE affects the surrounding cells via the receptor for AGEs (RAGE), thereby promoting the onset/progression of LSRD. We demonstrated that the intracellular accumulation of TAGE triggered numerous cellular disorders, and also that TAGE leaked into the extracellular space, thereby increasing extracellular TAGE levels in circulating fluids. Intracellular signaling and the production of reactive oxygen species are affected by extracellular TAGE and RAGE interactions, which, in turn, facilitate the intracellular generation of TAGE, all of which may contribute to the pathological changes observed in LSRD. In this review, we discuss the relationships between intracellular TAGE levels and numerous types of cell damage. The novel concept of the "TAGE theory" is expected to open new perspectives for research into LSRD.

Indexed as

Alzheimer DiseaseAnimalsCardiovascular DiseasesGlycation End Products, AdvancedHepatocytesHumansNon-alcoholic Fatty Liver DiseaseGlycation End Products, Advancedadvanced glycation end-products (AGEs)Alzheimer’s disease (AD)cardiovascular disease (CVD)lifestyle-related diseases (LSRD)non-alcoholic steatohepatitis (NASH)toxic AGEs (TAGE)

Identifiers

PMID33808036
PMCPMC8001776
OpenAlexW3133558932

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.